Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967803 | 1.00 | ADRA2A (0.47) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL2967801 | 1.00 | ADRA2A (0.47) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL18219540 | 0.83 | TAAR1 (0.39) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL4369978 | 0.83 | TAAR1 (0.37) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL13211529 | 0.81 | DPP4 (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL3022672 | 0.81 | DPP4 (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL12700905 | 0.81 | DPP4 (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL667241 | 0.81 | DPP4 (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL13211530 | 0.81 | DPP4 (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL4379944 | 0.79 | TAAR1 (0.36) | ADRA2AADRA2CLMNAHIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385084-B2 | Iron(II) catalysts containing tridentate PNP ligands, their synthesis, and use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-20 | — | — | US | disclosed |
| EP-3092075-A1 | IRON(II) CATALYSTS CONTAINING TRIDENTATE PNP LIGANDS, THEIR SYNTHESIS, AND USE THEREOF | The Governing Council Of The University Of Toronto (CA) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326202-A1 | IRON(II) CATALYSTS CONTAINING TRIDENTATE PNP LIGANDS, THEIR SYNTHESIS, AND USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2016-11-10 | — | — | US | disclosed |
| WO-2016029216-A2 | METHOD FOR PRODUCING AMIDINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-8716508-B2 | Method for preparing a metal catalyst | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2014-05-06 | — | — | US | disclosed |
| US-8716508-B2 | Method for preparing a metal catalyst | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2014-05-06 | — | — | US | disclosed |
| US-8658825-B2 | Method for the preparation of aminophosphine ligands and their use in metal catalysts | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2014-02-25 | — | — | US | disclosed |
| US-8658825-B2 | Method for the preparation of aminophosphine ligands and their use in metal catalysts | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2014-02-25 | — | — | US | disclosed |
| US-8658825-B2 | Method for the preparation of aminophosphine ligands and their use in metal catalysts | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2014-02-25 | — | — | US | disclosed |
| US-20120046479-A1 | METHOD FOR PREPARING A METAL CATALYST | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-20120046479-A1 | METHOD FOR PREPARING A METAL CATALYST | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-20100204514-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-08-12 | — | — | US | disclosed |
| US-20100204514-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-08-12 | — | — | US | disclosed |
| US-20100204514-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-08-12 | — | — | US | disclosed |
| WO-2010043027-A1 | METHOD FOR PREPARING A METAL CATALYST | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385084-B2 | Iron(II) catalysts containing tridentate PNP ligands, their synthesis, and use thereof | PNP, PNPO, FECH | ADRA2A 4606/4885ADRA2C 4539/4885LMNA 4266/4885 |
| US-20120046479-A1 | METHOD FOR PREPARING A METAL CATALYST | INPP5B, DNPEP, AOC1 | ADRA2A 3212/4885ADRA2C 3796/4885LMNA 446/4885 |
| US-20160326202-A1 | IRON(II) CATALYSTS CONTAINING TRIDENTATE PNP LIGANDS, THEIR SYNTHESIS, AND USE THEREOF | PNP, PNPO, FECH | ADRA2A 4738/4885ADRA2C 4705/4885LMNA 3609/4885 |
| US-20100204514-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | PNISR, PRMT9, PRMT8 | ADRA2A 3778/4885ADRA2C 3934/4885LMNA 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.